TrialJournal for immunotherapy of cancer2022

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.

Xiao Han et al.PubMed ↗Publisher ↗

No numbers read from the abstract.